(Melanoma) Is Tecentriq + Cotellic + Zelboraf Effective?
(Melanoma) Is Tecentriq + Cotellic + Zelboraf Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
(Melanoma) Is Tecentriq + Cotellic + Zelboraf Effective?
- March 30, 2020
- 1 min read
On December 13, 2019, Roche announced the "Efficacy and Safety Results from the IMspire150 Phase 3 Clinical Trial of the Anti-PD-L1 Antibody Tecentriq + MEK Inhibitor Cotellic + BRAF Inhibitor Zelboraf in Previously Untreated, BRAF V600 Mutation-Positive Melanoma Patients."
The IMspire150 trial was a multi-center, double-blind, controlled Phase 3 clinical trial that enrolled previously untreated, BRAF V600 mutation-positive melanoma patients divided into the following two groups. The primary endpoint was investigator-assessed progression-free survival, with secondary endpoints of overall survival, duration of response, and objective response rate.
Tecentriq group (Tecentriq + Cotellic + Zelboraf)
Placebo group (placebo + Cotellic + Zelboraf)
The results of this trial showed that the primary endpoint of investigator-assessed progression-free survival was clinically meaningful in the Tecentriq group. Regarding safety, the adverse events observed in the Tecentriq group were consistent with the safety profiles confirmed in current clinical trials, with no new adverse events identified.
Based on the results of the IMspire150 clinical trial, Levi Garraway concluded: In previously untreated, BRAF V600 mutation-positive melanoma patients, the anti-PD-L1 antibody Tecentriq + MEK inhibitor Cotellic + BRAF inhibitor Zelboraf is expected to become a new treatment option for patients.
[Disclaimer] The clinical trial data and pharmaceutical information translated by Medical Supporter are not intended to promote participation in clinical trials or the use of new drugs. The translated materials are for reference purposes only and do not constitute prescribing guidelines. Please consult your healthcare provider, and refer to the original text at the bottom of the article for accurate information.
Source: https://www.roche.com/media/releases/med-cor-2019-12-13.htm
#melanoma #Tecentriq #Cotellic #Zelboraf
-
Investigational Drug
-
Immunotherapy
(Lung Cancer) Topotecan and Topotecan + Berzosertib in Phase 2 Clinical Trial Results. (Lung Cancer) Is Trastuzumab deruxtecan Effective for HER2-Mutated Non-Small Cell Lung Cancer? (Lung Cancer) Is the Anti-B7-H3 Antibody-Drug Conjugate DS-7300 Effective?
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.